Recent news on Fosrenol

New hope for kidney dialysis patients  -  May 9, 2007
Manchester Evening News,Now the introduction of new drug, Fosrenol, means their pill burden can be cut by more than 75 per cent. Rachael Clegg reports. Retired GP Simon Jenkins,

Shire storms ahead with strong sales across the board  -  Apr 26, 2007
Pharma Times (subscription),Sales of Elaprase (idursulfase) for Hunter syndrome, launched in August 2006, reached $26.6 million, while turnover from Fosrenol (lanthanum carbonate) for

Shire and GSK upbeat over new drugs after patent losses  -  Apr 25, 2007
Telegraph.co.uk,Shire, Britain's third-biggest drugs maker, has just launched its drug for Hunter Syndrome, Elaprase, and is in the process of rolling out Fosrenol and

ROUNDUP Strong Q1 from Shire lifts hopes for full year; shares advance  -  Apr 25, 2007
Forbes,Shire still has a busy launch schedule ahead of it, with the roll out of Elaprase, anaemia treatment Dynepo and kidney disease drug Fosrenol across Europe

Shire storms ahead with strong sales across the board  -  26 Apr 2007
Pharma Times (subscription),Sales of Elaprase (idursulfase) for Hunter syndrome, launched in August 2006, reached $26.6 million, while turnover from Fosrenol (lanthanum carbonate) for

Shire and GSK upbeat over new drugs after patent losses  -  26 Apr 2007
Telegraph.co.uk,Shire, Britain's third-biggest drugs maker, has just launched its drug for Hunter Syndrome, Elaprase, and is in the process of rolling out Fosrenol and

SHIRE PLC - 1st Quarter Results  -  Apr 25, 2007
PR-Inside.com (Pressemitteilung),In the renal area, the launch of FOSRENOL in Europe continues, and we have gained significant market shares in many countries. DYNEPO was recently launched

Strong start to year for Shire  -  Apr 25, 2007
ShareCast,Attention deficit hyperactivity disorder (ADHD) drug Adderal XR saw sales rise 21% to $249.1m, while sales of hyperphosphatemia treatment Fosrenol almost

Shire launches Fosrenol  -  Apr 2, 2007
Healthcare RepublicShire has launched Fosrenol (lanthanum) for the treatment of hyperphosphataemia in chronic renal failure patients on haemodialysis, or continuous ambulatory

Shire Pharmaceuticals Extends 'Kidney-friendly' Cooking Program  -  Apr 10, 2007
PharmaLive.com (press release),FOSRENOL(R) is available in a broad range of dosage strengths, including the reformulated strengths of 500 mg, 750 mg and 1 g. With the reformulated doses,

Shire Pharmaceuticals Extends 'Kidney-Friendly' Cooking Program  -  Apr 10, 2007
PR Newswire (press release),FOSRENOL(R) is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD). FOSRENOL(R) is not indicated for the treatment of

Shire Pharmaceuticals Extends 'Kidney-Friendly' Cooking Program  -  Apr 10, 2007
PR Newswire (press release),FOSRENOL.com, or by calling 866-896-6152. About Hyperphosphatemia It is important for people with CKD Stage 5 to follow a low phosphorus diet, because most

ROUNDUP Strong Q1 from Shire lifts hopes for full year; shares advance  -  Apr 25, 2007
Forbes,Shire still has a busy launch schedule ahead of it, with the roll out of Elaprase, anaemia treatment Dynepo and kidney disease drug Fosrenol across Europe

American Kidney Fund launches Part D grant program  -  Apr 3, 2007
Renal Business Today,The program covers bone disease medications, including Fosrenol, Hecterol, Phoslo, Renagel, Sensipar and Zemplar. Burton added that the AKF hopes to add

American Kidney Fund Launches Medicare Part D Grant Program for ...  -  Apr 3, 2007
PR Web (press release),This program covers common bone disease medications, including Fosrenol®, Hectorol®, Phoslo®, Renagel®, Sensipar® and Zemplar®.

Shire Extends FOSRENOL(R) | at Hand Program to Cover Medicare Part ...  -  Mar 8, 2007
Drug Newswire (press release),Through the FOSRENOL(R) | at hand Patient Assistance Program (the original at hand offering) Shire provides help to patients who have no coverage for

UK Launch Expands Global Reach of FOSRENOL(R)  -  Mar 5, 2007
CNW Telbec (Communiqués de presse),Shire recently announced the launch of FOSRENOL (lanthanum carbonate) in the United Kingdom (UK) following the product's successful approval for the control

UK Launch Expands Global Reach of FOSRENOL(R)  -  Mar 5, 2007
Assodigitale,IT) FOSRENOL provides a new simplified treatment option to the estimated 1.4 million people on dialysis worldwide1 who are at risk from the serious

Shire extends Fosrenol assistance program  -  Feb 26, 2007
Renal Business Today,PHILADELPHIA—Shire PLC said today that it is extending its “Fosrenol at hand program� to provide the hyperphosphatemia drug free of charge to qualified

Fosrenol Launches In UK Today - New Option To Control Phosphate ...  -  Feb 22, 2007
Medical News Today (press release),Today Shire plc announced the launch of FOSRENOL® (lanthanum carbonate) in the United Kingdom following the product's authorisation as a phosphate binding

FOSRENOL(R) Launches in United Kingdom Today  -  Feb 22, 2007
Earthtimes.orgToday Shire plcannounced the launch of FOSRENOL(R) (lanthanum carbonate) in the UnitedKingdom following the product's authorisation as a phosphate binding

Shire launches Fosrenol in United Kingdom  -  Feb 22, 2007
United Press International22 (UPI) -- Shire said Thursday it launched Fosrenol in the United Kingdom for the treatment of patients with chronic kidney disease.

Shire plc: On Time Execution of Operating Plan Delivers Strong ...  -  Feb 20, 2007
MSN MoneyWe will benefit from the recent launches of DAYTRANA(TM) and ELAPRASE(TM) and roll-out of FOSRENOL(R) in Europe and anticipate three additional product

SHIRE PLC: Final Results  -  Feb 20, 2007
FinanzNachrichten.de,We will benefit from the recent launches of DAYTRANA™ and ELAPRASE™ and roll-out of FOSRENOL® in Europe and anticipate three additional product launches

Shire acquires New river, in black  -  Feb 20, 2007
ShareCast,Shire has a strong pipeline with the recent launches of Daytrana and Elaprase and roll-out of Fosrenol in Europe and three further product launches during

Nephrologists Report Practice Pattern Shifts in the Management of ...  -  Feb 1, 2007
PharmaLive.com (press release),Increased promotional noise in this market can be expected with Abbott supplementing Shire's efforts in the co-promotion of Fosrenol and with Fresenius

(PRN) - Reddy Ice Holdings, Inc. Announces Executive Appointments ...  -  Feb 22, 2007
Bolsamania.com,...(PRN) - FOSRENOL(R) Launches in United Kingdom Today ... [+]. (PRN) - Gin Rummy Proves Online Poker is 'Not The Only Game' ... [+]

Analysis: Raves for Shire's Vyvance deal  -  Feb 21, 2007
Science Daily (press release)The sales increase was driven by strong performances from Carbatrol/Equetro, Pentasa, Fosrenol and Elaprase. Shire said it anticipates revenue growth of

Shire buys New River Pharmaceuticals for $2.6 billion  -  Feb 21, 2007
Pharma Times (subscription),...reached $23.6 million, although turnover from Fosrenol (lanthanum carbonate) for high blood phosphate levels fell 16% to $44.8 million.

Drug group carves itself a special place  -  Feb 11, 2007
Times Online,Other leading Shire products that are already on the market include Carbatrol, for epilepsy, and Fosrenol, for bone disease.

Bayer Yakuhin Ltd. Has Filed Fosrenol(R) For The Treatment Of ...  -  Jan 4, 2007
Medical News Today (press release),Bayer Yakuhin Ltd. has submitted a marketing application for Fosrenol(R) (lanthanum carbonate) for the treatment of hyperphosphatemia in end stage renal

Bayer Yakuhin Ltd. has Filed Fosrenol(R) for the Treatment of ...  -  Dec 20, 2006
Japan Corporate News (press release),Bayer Yakuhin received an exclusive license from Shire International Licensing BV in December, 2003 to develop and sell Fosrenol(R) in Japan and completed

Genzyme Shares Jump on Analyst Reports  -  Jan 4, 2007
Houston Chronicle,Also, competition from Fosrenol could pose as another factor in shaving sales. "However, we believe Renagel's pressures are now widely known and that they

Bayer Yakuhin Ltd. has Filed Fosrenol(R) for the Treatment of ...  -  Dec 20, 2006
Japan Corporate News (press release),Bayer Yakuhin received an exclusive license from Shire International Licensing BV in December, 2003 to develop and sell Fosrenol(R) in Japan and completed

Shire releases 500 mg Fosrenol tablet  Oct 30, 2006
PHILADELPHIA --British drugmaker Shire Pharmaceuticals has added a 500 mg tablet of Fosrenol to its "reformulated portfolio" that will give patients more ... -Renal Business Today, Shire plc: Excellent Third Quarter With Execution Plan on Track ...  Oct 27, 2006
FOSRENOL(R) - Hyperphosphatemia - On October 18, Health Canada granted a marketing license application for FOSRENOL. Launch is now planned for Q2 2007. ... -PR Newswire (press release), Fosrenol Does Not Further Impact Cognitive Function Deterioration ...  Oct 21, 2006
..."Specifically, the study found that the use of FOSRENOL as a phosphate binder does not negatively affect cognitive function as compared to standard phosphate ... -Medical News Today (press release), Shire plc: Excellent Third Quarter With Execution Plan on Track ...  Oct 27, 2006
On October 18, Health Canada granted a marketing license application for FOSRENOL. ... The roll-out of FOSRENOL continues in the European markets. ... -Yahoo! News (press release) Newly Published Cognitive Function Data In Kidney International  Oct 18, 2006
Study shows Fosrenol(R) (lanthanum carbonate) does not further impact deterioration in cognitive function in CKD Stage 5 patients with hyperphosphatemia ... -PR Newswire (press release), AnorMED Reports Fiscal 2007 Second Quarter Results And An Update ...  Nov 2, 2006
Group received regulatory approvals in Germany on September 8, 2006 and in the United Kingdom on September 20, 2006 for FOSRENOL triggering milestone payments ... -MSN Money Shire Takes Forecast Higher  Oct 27, 2006
Shire said sales of its epilepsy drug Carbatrol grew 27% to $20.4 million, and revenue from the blood drug Fosrenol climbed 26% to $12.2 million. ... -TheStreet.com New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R ...  -  Nov 20, 2006
CNW Telbec (Communiqués de presse),Further Data Support the Contribution of FOSRENOL(R) (Lanthanum Carbonate) to the Overall Renal Health of the ESRD Patient While Reducing Mean Phosphate

New Analyses Demonstrate Positive Effect on Bone With Fosrenol ...  -  Nov 21, 2006
PipelineReview.com (press release),The 2 year data demonstrate that patients treated with FOSRENOL showed similar phosphate control and lower serum calcium levels than standard therapy.

New Analyses Demonstrate Positive Effect on Bone With FOSRENOL(R ...  -  Nov 20, 2006
PR Newswire Brasil (liberação de imprensa),BN003644 20 de novembro de 2006 11:32 HORALOCAL Further data support the contribution of FOSRENOL(R) (lanthanum carbonate) to the overall renal health of

New Analyses Demonstrate Positive Effect on Bone With Fosrenol ...  -  Nov 20, 2006
PharmaLive.com (press release),20 /CNW/ - New data presented on Friday 17th November at the American Society of Nephrology (ASN) Annual Meeting, show FOSRENOL is an effective phosphate

New Analyses Demonstrate Positive Effect on Bone With FOSRENOL(R ...  -  Nov 20, 2006
Antara (press release),New data presented on Friday 17th November at the American Society of Nephrology (ASN) Annual Meeting, show FOSRENOL is an effective phosphate binder with a

FOSRENOL(R) Data Show Evidence Of Trends Towards Improved Bone ...  -  Nov 18, 2006
Medical News Today (press release),Treatment with the phosphate binder FOSRENOL(R) (lanthanum carbonate) was associated with slight improvements in bone formation in chronic kidney disease

FOSRENOL(R) Data Show Evidence of Trends Towards Improved Bone ...  -  Nov 17, 2006
PR Newswire (press release),Additional studies presented at ASN document the efficacy and safety of the reformulated and higher-dose FOSRENOL(R) tablets.

Fosrenol data show evidence of trends towards improved bone ...  -  Nov 17, 2006
EurekAlert (press release),Additional studies presented at ASN document the efficacy and safety of the reformulated and higher-dose FOSRENOL tablets. Of the approximately 20 million

APS: New Analyses Demonstrate Positive Effect on Bone With .......  -  Nov 19, 2006
ANP Pers Support,This programme has demonstrated that FOSRENOL is an. effective phosphate binder with a good tolerability profile for long-term use. FOSRENOL

(PRN) - ITPC to Improve Communications Across Iraq With Nortel ...  -  Nov 20, 2006
Bolsamania.com,...(PRN) - New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy ... [+]

(PRN) - National Organization Awards Honor Contributions to Those ...  -  Nov 17, 2006
Bolsamania.com,...(PRN) - FOSRENOL(R) Data Show Evidence of Trends Towards Improved Bone Formation in CKD Stage 5 Patients, New Data Presented at ASN Meeting ... [+]

Shire plc: First 2006 Product Launched, Another Approved and ...  Jul 28, 2006
The European launch of FOSRENOL, a treatment for hyperphosphatemia, is also going well and we are looking to the continued roll-out of this product in the ... -PR Newswire

Shire reports Q2 sales up, profits down  Aug 1, 2006
...with the continued development and launch of five new products, including Daytrana, in 2006 and H1 2007, in addition to the roll-out of Fosrenol across Europe ... -PharmaLeader

AnorMED reports fiscal 2007 first quarter results and upcoming ...  Jul 28, 2006
We expect to receive additional milestone payments of US $6 million from Shire in Fiscal 2007 based on the receipt of additional approvals of FOSRENOL(TM) in ... -Drug Newswire

Shire reveals expected Q2 earnings dip UPDATE  Jul 28, 2006
...to support recently launched hyperactivity drug Daytrana and anaemia treatment Dynepo, the continued roll-out of kidney disease treatment Fosrenol, and to ... -Forbes

Fosrenol(R) Demonstrates Effective Phosphate Control With as Few ...  Jul 18, 2006
New data show calcium-free FOSRENOL (lanthanum carbonate) further reduces phosphate levels in dialysis patients previously receiving other monotherapies or ... -Antara

COMUNICADO: Fosrenol(R) Demonstrates Effective Phosphate Control ...  Jul 18, 2006
Breast feeding is not recommended when the mother is treated with Fosrenol. Tissue deposition of lanthanum has been shown with Fosrenol in animal studies. ... -Europa Press

Fosrenol(R) Demonstrates Effective Phosphate Control With as Few ...  Jul 18, 2006
...- New Data Show FOSRENOL Is an Effective Monotherapy - Leading to Improved Phosphate Reduction in Dialysis Patients Previously Receiving Alternative Phosphate ... -CNW Telbec (Communiqués de presse)

FOSRENOL® demonstrates effective phosphate control with as few as ...  Jul 19, 2006
BASINGSTOKE, UK | Jul 18, 2006 | New data show calcium-free FOSRENOL (lanthanum carbonate) further reduces phosphate levels in dialysis patients previously ... -PipelineReview.com

FOSRENOL demonstrates effective phosphate control  Jul 19, 2006
Basingstoke, England, (ANTARA News/PRNewswire-AsiaNet) - New Data Show FOSRENOL Is an Effective Monotherapy - Leading to Improved Phosphate Reduction in ... -Antara

Fosrenol(R) Demonstrates Effective Phosphate Control With as Few ...  Jul 18, 2006
Basingstoke, England (ots/PRNewswire) - - New Data Show FOSRENOL Is an Effective Monotherapy - Leading to Improved Phosphate Reduction in Dialysis Patients ... -news aktuell (Pressemitteilung)

(PRN) - Silicon Image to Present at 8th Annual Pacific Crest ...  Jul 18, 2006
...(PRN) - Fosrenol(R) Demonstrates Effective Phosphate Control With as Few as Three Tablets a Day ... [+. PRN) - The Coca-Cola Company ... -Bolsamania.com

(PRN) - AMCORE Financial, Inc. Reports 2nd Quarter Earnings ... ...  Jul 18, 2006
Technology Forum ... [+. PRN) - Fosrenol(R) Demonstrates Effective Phosphate Control With as Few as Three Tablets a Day ... [+. -Bolsamania.com

(PRN) - The Coca-Cola Company Reports Second Quarter and Year-To ...  Jul 18, 2006
...(PRN) - Fosrenol(R) Demonstrates Effective Phosphate Control With as Few as Three Tablets a Day ... [+. PRN) - The Home Depot To Offer Online Advertising ... ... -Bolsamania.com



New Analysis Confirms Long-term Safety, Tolerability and ...  Mar 20, 2006
...in Chronic Maintenance Hemodialysis Patients," examined the long-term tolerability and safety of the non-calcium phosphate binder FOSRENOL (lanthanum carbonate ... - PharmaLive.com

Shire Plc: Strong 2005 Performance Supports Positive Outlook  Feb 23, 2006
Pharmaceuticals Inc. (New River); - FOSRENOL higher strengths (750mg and 1000mg) launched in the US. 2005 Business Development. - Sale ... - International News Service,

Shire annual underlying earnings fall  Feb 23, 2006
AFX) - British drug developer Shire PLC reported a 5 pct fall in underlying annual earnings, dented by the cost of launching two new drugs, Fosrenol for renal ... - Forbes

Award for scientist's platinum work - 22nd February 2006  Feb 22, 2006
Development led by Dr Abrams on drugs based on platinum gave rise to NX473 and Fosrenol, as well as promising future stem cell products and HIV inhibitors. ... - Platinum today,

AnorMED's CEO Michael Abrams receives prestigious Julia Levy Award ...  Feb 21, 2006
Dr. Abrams in recognition of his critical involvement in the development of platinum-based cancer chemotherapeutic drugs leading to NX473; and FOSRENOL(TM), a ... - Canada NewsWire,

AnorMED reports fiscal 2006 third quarter results and announces ...  Feb 7, 2006
I safety study of MOZOBIL in cardiac patients - Receive milestone payments from Shire contingent upon additional European approvals for FOSRENOL - Select lead ... - MSN Money

AnorMED reports fiscal 2006 third quarter results and announces ...  Feb 7, 2006
I safety study of MOZOBIL in cardiac patients - Receive milestone payments from Shire contingent upon additional European approvals for FOSRENOL - Select lead ... - CNW Telbec (Communiqués de presse)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional